Serial CT response score (CTRS) predicted overall survival (OS) more effectively than existing imaging-based measures in patients with advanced non–small cell lung cancer (NSCLC) receiving immune ...
A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...
In this phase 2 study, researchers explored whether fecal microbiota transplant could overcome resistance to immune checkpoint inhibition.
Daiichi Sankyo’s development of antibody-drug conjugates continues to hit turbulence. | Daiichi Sankyo’s development of ADCs ...
The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...
Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales. | Astellas surpassed ...
US biotech Gilead Sciences today announced that its Trodelvy (sacituzumab govitecan-hziy) has now been added to the National ...
AstraZeneca & Daiichi Sankyo’s Datroway granted Priority Review in US as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy: Cambridge ...
Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.
MedPage Today on MSN
For Your Patients: A Look at Promising New Treatments for Gastric Cancer
Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...
DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results